Optimizing Quality Tolerance Limits Monitoring in Clinical Trials Through Machine Learning Methods
Liwen Wu
Co-Author
Takeda Pharmaceuticals
Lei Yan
First Author
Florida State University
Lei Yan
Presenting Author
Florida State University
Wednesday, Aug 6: 11:45 AM - 11:55 AM
1670
Contributed Papers
Music City Center
The traditional clinical trial monitoring process, which relies heavily on site visits and manual review of accumulative patient data reported through Electronic Data Capture system, is time-consuming and resource-intensive. The recently emerged risk-based monitoring (RBM) and quality tolerance limit (QTL) framework offers a more efficient alternative solution to traditional source data verification based quality assurance. These frameworks aim at proactively identifying systematic issues that impact patient safety and data integrity. In this paper, we proposed a machine learning enabled approach to facilitate real-time, automated monitoring of clinical trial QTL risk assessment. Unlike the traditional quality assurance process, where QTLs are evaluated based on single-source data and arbitrary defined fixed threshold, we utilize the QTL-ML framework to integrate information from multiple clinical domains to predict the clinical QTL of variety types at program, study, site and patient level. Moreover, our approach is assumption-free, relying not on historical expectations but on dynamically accumulating trial data to predict quality tolerance limit risks in an automated manner.
good clinical practice
risk-based monitoring
quality tolerance limits
machine learning
Main Sponsor
Biopharmaceutical Section
You have unsaved changes.